Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

PanOptica gets rights to OSI Pharma's PAN90806

Executive Summary

Astellas Pharma Inc.’s OSI Pharmaceuticals Inc. has granted PanOptica Inc. (ophthalmology therapeutics) exclusive global rights to preclinical PAN90806, a small-molecule selective inhibitor of VEGF for potential use as a topical treatment for neovascular age-related macular degeneration (neovascular AMD or “wet” AMD).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Reverse Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register